Oncology Views & Analysis

Views & Analysis

ASCO 2018 - Sunday 3rd June: Opdivo/Nektar, AbbVie's new leu...

Bristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Nektar Therapeutics. But new early stage data from the cocktail pres

Views & Analysis

ASCO 2018 - Friday 1st and Saturday 2nd June: Bluebird Bio's...

The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance in cancer therapy this year – and latest clinical trial results from t

Views & Analysis

ASCO 2018 Preview – what to expect from this year’s conferen...

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the year for cancer medicine.

Views & Analysis

Bahija Jallal: pharma’s Woman of the Year in a landmark 12 m...

AstraZeneca’s Bahija Jallal was named the Healthcare Businesswomen’s Association (HBA) Women of the Year for 2017 – in what turned out to a watershed year for women’s rights.

Views & Analysis

Improving oncology KOL engagement

Combining technology with human insights is a powerful tool in identifying and engaging effectively with oncology experts.

Views & Analysis

Kite and Sangamo come together in $3bn cancer gene editing a...

Two pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious alliance to develop new cancer therapies.

ASCO 2018 - Sunday 3rd June: Opdivo/Nektar, AbbVie's new leu...

ASCO 2018 - Friday 1st and Saturday 2nd June: Bluebird Bio's...

ASCO 2018 Preview – what to expect from this year’s conferen...

Bahija Jallal: pharma’s Woman of the Year in a landmark 12 m...

Improving oncology KOL engagement

Kite and Sangamo come together in $3bn cancer gene editing a...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Views & Analysis

Editor's Picks